Dr Patrizia Giannatempo (RCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy), Prof Andrea Necchi (The Vita-Salute San Raffaele University, Milan, Italy), Dr Michiel Simon Van Der Heijden (Netherlands Cancer Institute, Amsterdam, Netherlands) and Prof Simon Crabb (University Hospital Southampton NHS Foundation Trust, Southampton, UK) discuss bladder cancer updates from ESMO 2024.

The panel begin by discussing the changing patient pathway in metastatic urothelial cancer. They address how the evolving guidelines are affecting treatment sequencing and where different treatments fit into the overall treatment landscape. There is also a discussion on the impact of these changes on treatment guidelines.

Professor Necchi specifically covers FGFR testing, and the panel examines the reasons, methods, and timing for conducting these tests. They delve into optimising patient care, managing adverse events, and exploring additional treatment options, with a focus on future developments.

The panel reviews key data from the SunRISe-1, SunRISe-4, NIAGARA, and TOMBOLA trials.